Alcon introduces advanced Clareon IOLs in India
ALC
+1.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
BENGALURU – Alcon (NYSE:ALC), a global leader in eye care, has announced the launch of its Clareon family of intraocular lenses (IOLs) in India. The Clareon IOLs, which represent over two decades of innovation, are designed to provide patients with enduring clarity of vision after cataract surgery.
The lenses are made from a glistening-free material, which Alcon claims to have among the lowest levels of haze and subsurface nanoglistenings compared to leading competitor IOLs.
The Clareon portfolio includes the Clareon PanOptix and Clareon Vivity, both of which employ advanced technologies aimed at improving patients’ vision. The Clareon PanOptix is a trifocal IOL that has been implanted more than 2.2 million times globally and boasts a 99.2% patient satisfaction rate.
It is designed to deliver clear vision at various distances, potentially offering spectacle independence for patients. The Clareon Vivity, on the other hand, utilizes wavefront-shaping X-WAVE technology to offer a low rate of visual disturbances and aims to provide monofocal-like certainty for patients with presbyopia.
According to Alcon, the Clareon IOLs are inserted using the Monarch IV Delivery System, which allows for precise and controlled implantation. The company emphasizes that the Clareon IOLs share design characteristics with Alcon’s leading IOLs, which are intended to help deliver the outcomes surgeons expect, such as sharp vision and reduced glare.
The launch of Clareon IOLs in India is timely, as the number of cataract surgeries is expected to rise significantly in the coming years due to an aging global population and longer life expectancies. More than 28 million cataract surgeries are performed annually worldwide, and this number is projected to increase by 3-4% per year, potentially reaching 60 million by 2045.
Dr. Shail Vasavada, one of the early adopters of Clareon IOLs, praised the new material and delivery system for their clarity and consistent refractive outcomes, expressing confidence in the high rate of patient satisfaction.
Alcon’s commitment to eye care innovation is underscored by the launch of Clareon IOLs in India, which is based on extensive research, including 30 published studies. However, as with any medical device, the risks and benefits should be carefully considered by surgeons and patients alike.
This news is based on a press release statement from Alcon.
